These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 23156431)

  • 1. [iPS cell technology-based strategies for the treatment of diabetic nephropathy].
    Osafune K
    Nihon Rinsho; 2012 Jul; 70 Suppl 5():419-23. PubMed ID: 23156431
    [No Abstract]   [Full Text] [Related]  

  • 2. iPS cell technology-based research for the treatment of diabetic nephropathy.
    Osafune K
    Semin Nephrol; 2012 Sep; 32(5):479-85. PubMed ID: 23062989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status and perspective of regenerative medicine for diabetic nephropathy].
    Matsui S; Osafune K
    Nihon Rinsho; 2016 Apr; 74 Suppl 2():207-11. PubMed ID: 27266089
    [No Abstract]   [Full Text] [Related]  

  • 4. Prospects for pluripotent stem cell therapies: into the clinic and back to the bench.
    Grabel L
    J Cell Biochem; 2012 Feb; 113(2):381-7. PubMed ID: 21928325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Induced pluripotent stem (iPS) cell-based cell therapy for muscular dystrophy: current progress and future prospects].
    Nishiyama T; Takeda S
    Brain Nerve; 2012 Jan; 64(1):39-46. PubMed ID: 22223500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced pluripotent stem cells for peripheral nerve regeneration.
    Xu W; Cox CS; Li Y
    J Stem Cells; 2011; 6(1):39-49. PubMed ID: 22997844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research for cell therapy by induced pluripotent stem cell].
    Sakurai H; Yamanaka S
    Nihon Rinsho; 2011 Dec; 69(12):2114-8. PubMed ID: 22242307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening.
    Song M; Paul S; Lim H; Dayem AA; Cho SG
    Arch Pharm Res; 2012 Feb; 35(2):245-60. PubMed ID: 22370779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology.
    Chang YL; Chen SJ; Kao CL; Hung SC; Ding DC; Yu CC; Chen YJ; Ku HH; Lin CP; Lee KH; Chen YC; Wang JJ; Hsu CC; Chen LK; Li HY; Chiou SH
    Cell Transplant; 2012; 21(1):313-32. PubMed ID: 21669041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of clinically relevant "induced pluripotent stem" (iPS) cells.
    Heffernan C; Sumer H; Verma PJ
    J Stem Cells; 2011; 6(3):109-27. PubMed ID: 23264997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A challenge towards the clinical application of induced pluripotent stem cell technology for the treatment of Parkinson's disease].
    Morizane A; Takahashi J
    Brain Nerve; 2012 Jan; 64(1):29-37. PubMed ID: 22223499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells.
    Zhou W; Freed CR
    Stem Cells; 2009 Nov; 27(11):2667-74. PubMed ID: 19697349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of induced pluripotent stem cells into functional oligodendrocytes.
    Czepiel M; Balasubramaniyan V; Schaafsma W; Stancic M; Mikkers H; Huisman C; Boddeke E; Copray S
    Glia; 2011 Jun; 59(6):882-92. PubMed ID: 21438010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. iPS cells in type 1 diabetes research and treatment.
    Maehr R
    Clin Pharmacol Ther; 2011 May; 89(5):750-3. PubMed ID: 21430661
    [No Abstract]   [Full Text] [Related]  

  • 15. Highly efficient generation of definitive endoderm lineage from human induced pluripotent stem cells.
    Sekine K; Takebe T; Suzuki Y; Kamiya A; Nakauchi H; Taniguchi H
    Transplant Proc; 2012 May; 44(4):1127-9. PubMed ID: 22564643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of mouse induced pluripotent stem cells from different genetic backgrounds using Sleeping beauty transposon mediated gene transfer.
    Muenthaisong S; Ujhelly O; Polgar Z; Varga E; Ivics Z; Pirity MK; Dinnyes A
    Exp Cell Res; 2012 Nov; 318(19):2482-9. PubMed ID: 22846649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Utilization of the ES/iPS cell technology for hematopoietic stem cell transplantation].
    Otsu M; Nakauchi H
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():146-50. PubMed ID: 23133943
    [No Abstract]   [Full Text] [Related]  

  • 18. An introduction to induced pluripotent stem cells.
    Hanley J; Rastegarlari G; Nathwani AC
    Br J Haematol; 2010 Oct; 151(1):16-24. PubMed ID: 20666774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Induction and characterization of induced pluripotent stem (iPS) cells: a review].
    Cheng D; Lei L; Lu Z; Li Z; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2010 Apr; 26(4):421-30. PubMed ID: 20575428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Application of iPS cell technology for NKT cell-targeted adjuvant therapy in mice].
    Yamada D; Koseki H
    Rinsho Ketsueki; 2010 Nov; 51(11):1661-7. PubMed ID: 21157129
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.